Form 4: SUPN Executive Acquires Performance Share Units
Insider Transaction Report
Supernus Pharmaceuticals' Senior VP of IP and CSO, Padmanabh P. Bhatt, reported the acquisition of 1,500 performance share units and beneficial ownership of 13,718 common shares.
Summary
- Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, Inc. (SUPN), reported changes in beneficial ownership.
- Following the reported transactions, Bhatt beneficially owns 13,718 shares of Common Stock directly.
- Bhatt acquired 1,500 Performance Share Units on November 13, 2025.
- These Performance Share Units were initially awarded on February 22, 2022, with a portion vesting upon achieving individual performance objectives set on May 3, 2022.
- The Performance Share Units have an exercise price of $0 and represent 1,500 underlying shares of Common Stock.
Sentiment
Score: 6
Explanation: The acquisition of performance share units by an executive is generally viewed as a neutral to slightly positive event, indicating alignment of interests and achievement of performance goals, but it's a routine compensation event rather than a significant strategic move.
Positives
- An executive acquiring performance share units can signal alignment of management interests with shareholder value.
- The vesting of performance share units indicates the achievement of individual performance objectives.
Stakeholder Impact
- Shareholders: Executive's increased equity stake through performance units aligns their interests with shareholder value creation.
Key Dates
| Date | Description |
|---|---|
| 02/22/2022 | Performance Share Units initially awarded to Reporting Person. |
| 05/03/2022 | Individual performance objectives for Performance Share Units established. |
| 11/13/2025 | Transaction date for acquisition of Performance Share Units and reported beneficial ownership of Common Stock. |
| 11/14/2025 | Signature date of the reporting person's attorney-in-fact. |
Recommendation
holdThis Form 4 filing reports a routine executive compensation event involving the acquisition of performance share units. While it indicates management's continued alignment with company performance, it does not present new information that would fundamentally alter the investment thesis for Supernus Pharmaceuticals, warranting a 'hold' recommendation based solely on this filing.
Keywords
Supernus Pharmaceuticals, SUPN, Form 4, Insider Trading, Beneficial Ownership, Performance Share Units, Executive Compensation, Stock Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.